1
|
Ono M, Matsuura K, Kono M, Ohnishi K, Takayama Y, Shoda H, Iwamoto Y, Kagemoto M. Long-Term Results of a Phase II Study of Accelerated Hyperfractionated Thoracic Radiotherapy with Dose Escalation to 54 Gy for Limited-Stage Small-Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2023; 117:e45. [PMID: 37785450 DOI: 10.1016/j.ijrobp.2023.06.747] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) The combination of accelerated hyperfractionated thoracic radiotherapy (AHF-TRT) of 45 Gy and concurrent chemotherapy is the standard treatment for limited-stage small-cell lung cancer (LS-SCLC). However, the optimal dose and fractionation remain controversial. We herein report the results of a phase II study investigating the utility of dose escalation to 54 Gy on AHF-RT for LS-SCLC. MATERIALS/METHODS We enrolled patients ≤80 years old with treatment-naïve confirmed LS-SCLC and an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. The radiation dose was 54 Gy delivered in 36 fractions in 18 treatment days over 3.6 weeks. The chemotherapy regimens were PE (cisplatin and etoposide)- or CE (carboplatin and etoposide)-based. AHF-TRT was given in 2 phases: patients initially received 36 Gy to the gross tumor plus uninvolved mediastinal nodes, followed by a boost to the gross tumor of 18 Gy. All patients were treated with three-dimensional conformal radiation therapy with multiple fields to reduce the elevated dose volume to the surrounding tissues, such as the lungs and esophagus, as much as possible. All patients were evaluated for the overall survival (OS), progression-free survival (PFS), and non-hematological toxicity. RESULTS Between 2013 and 2016, a total of 13 patients were enrolled in the present study. All the patients were assessable for the response and toxicity. The median age was 67 (range, 54-78) years old, and 9 patients were male, while 4 were female. Twelve patients had a ECOG performance status of 0. The numbers of patients with Stage IIA, IIB, IIIA, and IIIB disease were one, one, eight, and three, respectively. The median follow-up for all patients was 79 (range, 13-107) months, and that for surviving patients was 90 (range, 79-107) months. The patterns of failure were locoregional-only recurrence in 0% (0 patients), both locoregional and distant in 15.4% (2 patients), and distant-only in 30.8% (4 patients). Recurrence from the elective nodal irradiation area was seen in 0% (0 patients). The 1-, 3-, 5-, and 7-year OS rates were 100%, 76.9%, 53.9%, and 44.9%, respectively, and the median OS was 83.0 months. The 1-, 3-, 5-, and 7-year PFS rates were 76.9%, 53.9%, 53.9%, and 44.9%, respectively, and the median PFS was 83.0 months. No patient experienced a grade ≥3 non-hematological adverse effect, such as esophagitis or pneumonitis, during treatment or follow-up. Grade 2 pneumonitis was observed in 2 patients (15.4%), Grade 2 esophagitis was observed in 12 patients (92.3%), and Grade 2 esophageal pain was observed in 2 patients (15.4%). CONCLUSION In this study, AHF-TRT of 54 Gy with concurrent PE- or CE-based regimens resulted in a good OS and PFS without increasing severe toxicity. Although this regimen needs to be evaluated in more patients to fully confirm its efficacy, these outcomes suggest that dose escalation to 54 Gy may be a promising radical treatment for LS-SCLC.
Collapse
Affiliation(s)
- M Ono
- Clinical training division, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Department of Radiation Oncology, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan
| | - K Matsuura
- Department of Radiation Oncology, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan
| | - M Kono
- Department of Medical Oncology, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan
| | - K Ohnishi
- Department of Radiation Oncology, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan
| | - Y Takayama
- Department of Respiratory Medicine, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan
| | - H Shoda
- Department of Respiratory Medicine, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan
| | - Y Iwamoto
- Department of Medical Oncology, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan
| | - M Kagemoto
- Department of Radiation Oncology, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan
| |
Collapse
|
2
|
Tsutsui T, Fujiwara T, Matsumoto Y, Kimura A, Kanahori M, Arisumi S, Oyamada A, Ohishi M, Ikuta K, Tsuchiya K, Tayama N, Tomari S, Miyahara H, Mae T, Hara T, Saito T, Arizono T, Kaji K, Mawatari T, Fujiwara M, Takasaki M, Shin K, Ninomiya K, Nakaie K, Antoku Y, Iwamoto Y, Nakashima Y. Geriatric nutritional risk index as the prognostic factor in older patients with fragility hip fractures. Osteoporos Int 2023:10.1007/s00198-023-06753-3. [PMID: 37067545 DOI: 10.1007/s00198-023-06753-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/06/2022] [Accepted: 04/06/2023] [Indexed: 04/18/2023]
Abstract
This study investigated the long-term survival and incidence of secondary fractures after fragility hip fractures. The 5-year survival rate was 62%, and the mortality risk was seen in patients with GNRI < 92. The 5-year incidence of secondary fracture was 22%, which was significantly higher in patients with a BMI < 20. BACKGROUND Malnutrition negatively influences the postoperative survival of patients with fragility hip fractures (FHFs); however, little is known about their association over the long term. OBJECTIVE This study evaluated the ability of the geriatric nutritional risk index (GNRI) as a risk factor for long-term mortality after FHFs. METHODS This study included 623 Japanese patients with FHFs over the age of 60 years. We prospectively collected data on admission and during hospitalization and assessed the patients' conditions after discharge through a questionnaire. We examined the long-term mortality and the incidence of secondary FHFs and assessed the prognostic factors. RESULTS The mean observation period was 4.0 years (range 0-7 years). The average age at the time of admission was 82 years (range 60-101 years). The overall survival after FHFs (1 year, 91%; 5 years, 62%) and the incidence of secondary FHFs were high (1 year, 4%; 5 years, 22%). The multivariate Cox proportional hazard analysis revealed the risk factors for mortality as older age (hazard ratio [HR] 1.04), male sex (HR 1.96), lower GNRI score (HR 0.96), comorbidities (malignancy, HR 2.51; ischemic heart disease, HR 2.24; revised Hasegawa dementia scale ≤ 20, HR 1.64), no use of active vitamin D3 on admission (HR 0.46), and a lower Barthel index (BI) (on admission, HR 1.00; at discharge, HR 0.99). The GNRI scores were divided into four risk categories: major risk (GNRI, < 82), moderate risk (82-91), low risk (92-98), and no risk (> 98). Patients at major and moderate risks of GNRI had a significantly lower overall survival rate (p < 0.001). Lower body mass index (BMI) was also identified as a prognostic factor for secondary FHFs (HR 0.88 [p = 0.004]). CONCLUSIONS We showed that older age, male sex, a lower GNRI score, comorbidities, and a lower BI are risk factors for mortality following FHFs. GNRI is a novel and simple predictor of long-term survival after FHFs.
Collapse
Affiliation(s)
- T Tsutsui
- Department of Orthopaedic Surgery, Graduate School of Medical Science, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan
| | - T Fujiwara
- Department of Orthopaedic Surgery, Graduate School of Medical Science, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
| | - Y Matsumoto
- Department of Orthopaedic Surgery, Graduate School of Medical Science, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan
| | - A Kimura
- Department of Orthopaedic Surgery, Graduate School of Medical Science, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan
| | - M Kanahori
- Department of Orthopaedic Surgery, Graduate School of Medical Science, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan
| | - S Arisumi
- Department of Orthopaedic Surgery, Graduate School of Medical Science, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan
| | - A Oyamada
- Department of Orthopaedic Surgery, Saga Handicapped Children's Hospital, Saga, Japan
| | - M Ohishi
- Department of Orthopaedic Surgery, Chihaya Hospital, Fukuoka, Japan
| | - K Ikuta
- Department of Orthopaedic Surgery, Karatsu Red Cross Hospital, Saga, Japan
| | - K Tsuchiya
- Department of Orthopaedic Surgery, Japan Community Healthcare Organization, Kyushu Hospital, Fukuoka, Japan
| | - N Tayama
- Department of Orthopaedic Surgery, Steel Memorial Yawata Hospital, Fukuoka, Japan
| | - S Tomari
- Department of Orthopaedic Surgery, Japanese Red Cross Fukuoka Hospital, Fukuoka, Japan
| | - H Miyahara
- Department of Orthopaedic Surgery, National Hospital Organization Kyushu Medical Centre, Fukuoka, Japan
| | - T Mae
- Department of Orthopaedic Surgery, Saga-Ken Medical Centre Koseikan, Saga, Japan
| | - T Hara
- Department of Orthopaedic Surgery, Aso Iizuka Hospital, Fukuoka, Japan
| | - T Saito
- Department of Orthopaedic Surgery, Fukuoka City Hospital, Fukuoka, Japan
| | - T Arizono
- Department of Orthopaedic Surgery, Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers, Fukuoka, Japan
| | - K Kaji
- Department of Orthopaedic Surgery, Kyushu Rosai Hospital, Fukuoka, Japan
| | - T Mawatari
- Department of Orthopaedic Surgery, Hamanomachi Hospital, Fukuoka, Japan
| | - M Fujiwara
- Department of Orthopaedic Surgery, Sada Hospital, Fukuoka, Japan
| | - M Takasaki
- Department of Orthopaedic Surgery, Harasanshin Hospital, Fukuoka, Japan
| | - K Shin
- Department of Orthopaedic Surgery, Saiseikai Yahata General Hospital, Fukuoka, Japan
| | - K Ninomiya
- Department of Orthopaedic Surgery, Koga Hospital 21, Fukuoka, Japan
| | - K Nakaie
- Department of Orthopaedic Surgery, National Hospital Organization Fukuoka-Higashi Medical Centre, Fukuoka, Japan
| | - Y Antoku
- Faculty of Medicine, Hospital Informatic Centre, Oita University, Oita, Japan
| | - Y Iwamoto
- Department of Orthopaedic Surgery, Kyushu Rosai Hospital, Fukuoka, Japan
| | - Y Nakashima
- Department of Orthopaedic Surgery, Graduate School of Medical Science, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan
| |
Collapse
|
3
|
Asao Y, Iwamoto Y, Chea C, Chher T, Mitsuhata C, Naito M, Kozai K. The effect of improving oral health literacy among teachers on the oral health condition of primary schoolchildren in Cambodia. EUROPEAN JOURNAL OF PAEDIATRIC DENTISTRY 2022; 23:321-326. [PMID: 36511904 DOI: 10.23804/ejpd.2022.23.04.12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
AIM In Cambodia, civil unrest has led to insufficient and inaccessible dental health services. Oral health education and awareness are lacking, thus childhood dental caries is highly prevalent. This study aimed to examine the effects of an oral health education programme for public primary school teachers on the pupils' oral health. METHODS Between 2011 and 2015, an oral health education workshop was presented annually to primary school educators employed at a public school in Siem Reap, Cambodia. Oral screenings of 2,637 pupils (grades 1-6; subdivided between the lower 1-3 and upper 4-6 grades) were undertaken and the prevalence of dental caries, mean number of DFT, and mean percentage of DFT rate were calculated. CONCLUSION Despite the persistently high prevalence of dental caries, the oral health status of the schoolchildren improved every year. Participation in the workshops may have improved the teachers' ability to provide oral healthcare instructions, leading to the reduced dental caries prevalence among pupils.
Collapse
Affiliation(s)
- Y Asao
- Department of Pediatric Dentistry, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| | - Y Iwamoto
- Department of Pediatric Dentistry, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| | - C Chea
- Department of Oral Pathology, Faculty of Odonto-Stomatology, Health Sciences Institute of Royal Cambodian Armed Forces, Phnom Penh, Cambodia Faculty of Odonto-Stomatology, University of Health Sciences, Phnom Penh, Cambodia Faculty of Dentistry, University of Puthisastra, Phnom Penh, Cambodia Faculty of Dentistry, International University, Phnom Penh, Cambodia
| | - T Chher
- Oral Health Bureau, Preventive Medicine Department, Ministry of Health Cambodia
| | - C Mitsuhata
- Department of Pediatric Dentistry, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| | - M Naito
- Department of Oral Epidemiology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| | - K Kozai
- Department of Pediatric Dentistry, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| |
Collapse
|
4
|
Umehara T, Katayama N, Kaneguchi A, Iwamoto Y, Tsunematsu M, Kakehashi M. Models to predict prognosis in older patients with heart failure complicated by pre-frailty and frailty: a pilot prospective cohort study. Hong Kong Med J 2022; 28:356-366. [PMID: 36131623 DOI: 10.12809/hkmj209103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/15/2023] Open
Abstract
INTRODUCTION There are no clinical prediction models to predict the prognosis of pre-frailty or frailty in patients with heart failure. We aimed to develop prediction models for the prognosis of pre-frailty and frailty in older patients with heart failure using the classification and regression tree (CART) method; we then tested the predictive accuracies of the developed models. METHODS Patients with pre-frailty or frailty at admission were divided into improved and non-improved groups. The CART method was used to establish two models: A, which predicted the presence or absence of pre-frailty improvement during hospitalisation; and B, which predicted the presence or absence of frailty improvement during hospitalisation. RESULTS Patients with heart failure complicated by pre-frailty (n=28) or frailty (n=156) were included. In model A, the accuracy of predicting pre-frailty improvement was high; the best predictor was single-leg standing time at admission, followed by left ventricular ejection fraction at admission. In model B, the accuracy of predicting frailty improvement was moderate; the best predictor was hand grip strength at admission, followed by estimated glomerular filtration rate at admission, haemoglobin level at admission, and change in single-leg standing time during hospitalisation. The areas under the receiver operating characteristic curves of the CART models were 0.96 and 0.84 in models A and B, respectively. CONCLUSION Although conditions at admission may predict the improvement of pre-frailty and frailty during hospitalisation, cardiac rehabilitation that improves single-leg standing time may help to improve frailty, particularly when conditions at admission are poor.
Collapse
Affiliation(s)
- T Umehara
- Department of Rehabilitation, Faculty of Rehabilitation, Hiroshima International University, Higashi-Hiroshima, Japan
- Department of Rehabilitation, Saiseikai Kure Hospital, Kure, Japan
| | - N Katayama
- Department of Rehabilitation, Kure Kyosai Hospital, Kure, Japan
| | - A Kaneguchi
- Department of Rehabilitation, Faculty of Rehabilitation, Hiroshima International University, Higashi-Hiroshima, Japan
| | - Y Iwamoto
- Department of Neuromechanics, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| | - M Tsunematsu
- Department of Health Informatics, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| | - M Kakehashi
- Department of Health Informatics, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| |
Collapse
|
5
|
Terazono H, Tsuchiya M, Maki Y, Yoshikawa N, Kawahara Y, Nishimura K, Shinohara K, Ogawa D, Mori R, Iwamoto Y, Itagaki F, Masuko H, Yonemura M, Uchida M. Evaluation of a Webinar for Pharmacists Learning Basic Clinical-Oncology during COVID-19 Pandemic in Japan. Biol Pharm Bull 2022; 45:856-862. [PMID: 35786594 DOI: 10.1248/bpb.b21-00844] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/09/2022]
Abstract
It is essential for oncology pharmacists to update their knowledge, skills, and ethical attitudes. The Japanese Society of Pharmaceutical Oncology is an academic society for healthcare professionals involved in cancer treatment. It has conducted in-person seminars every year to cultivate the knowledge necessary for practicing advanced cancer medicine. Owing to the coronavirus disease (COVID-19) pandemic, the society was obligated to conduct a web-based seminar this year. A questionnaire survey was conducted before and after the webinar to explain how it works and to assess the learning attitudes of beginner and moderately skilled pharmacists in the field of oncology. Questionnaire surveys were conducted with the participants before and after watching the webinar. The questionnaires sought to determine participants' perspectives on the webinar and their knowledge of the seven modules. Of the 1756 webinar attendees, 1661 (94.6%) answered the pre-webinar survey and 1586 (90.3%) answered the post-webinar survey. Results indicate that the median post-webinar knowledge score was significantly higher than the median pre-webinar score (p < 0.001) in all modules. Principal component analysis of the degree of knowledge of seven modules revealed that the improved score group consisted of those from younger age groups, with less experience as pharmacists, non-society members, and those with less experience in past society seminars. Moreover, the web-based seminar provided a uniform learning effect throughout the country without distinguishing between urban and rural learners. The web-based educational program was an acceptable educational tool for Japanese oncology pharmacists.
Collapse
Affiliation(s)
- Hideyuki Terazono
- Department of Pharmacy, Kagoshima University Hospital.,Education and Training Committee, Japanese Society of Pharmaceutical Oncology (JASPO)
| | - Masami Tsuchiya
- Education and Training Committee, Japanese Society of Pharmaceutical Oncology (JASPO).,Department of Pharmacy, Miyagi Cancer Center
| | - Yosuke Maki
- Education and Training Committee, Japanese Society of Pharmaceutical Oncology (JASPO).,Department of Pharmacy, Nagasaki Medical Center
| | - Naoki Yoshikawa
- Education and Training Committee, Japanese Society of Pharmaceutical Oncology (JASPO).,Department of Pharmacy, University of Miyazaki Hospital
| | - Yosuke Kawahara
- Education and Training Committee, Japanese Society of Pharmaceutical Oncology (JASPO).,Department of Pharmacy, JR Tokyo General Hospital
| | - Keiko Nishimura
- Education and Training Committee, Japanese Society of Pharmaceutical Oncology (JASPO).,Sogo Medical Co., Ltd
| | - Keisuke Shinohara
- Education and Training Committee, Japanese Society of Pharmaceutical Oncology (JASPO).,Department of Pharmacy, Saku Central Hospital Advanced Care Center
| | - Daisuke Ogawa
- Education and Training Committee, Japanese Society of Pharmaceutical Oncology (JASPO).,Department of Pharmacy, Matsuda Hospital
| | - Riho Mori
- Education and Training Committee, Japanese Society of Pharmaceutical Oncology (JASPO).,Department of Pharmacy, Tokushima Municipal Hospital
| | - Yoshihiro Iwamoto
- Education and Training Committee, Japanese Society of Pharmaceutical Oncology (JASPO).,Department of Pharmacy, National Cancer Center Hospital East
| | - Fumio Itagaki
- Education and Training Committee, Japanese Society of Pharmaceutical Oncology (JASPO).,Department of Clinical & Pharmaceutical Sciences, Faculty of Pharma Sciences, Teikyo University
| | - Hiroyuki Masuko
- Education and Training Committee, Japanese Society of Pharmaceutical Oncology (JASPO).,Department of Pharmacy, Hokkaido Medical Center for Child Health And Rehabilitation
| | - Masahito Yonemura
- Education and Training Committee, Japanese Society of Pharmaceutical Oncology (JASPO).,Department of Pharmacy, National Cancer Center Hospital East
| | - Mayako Uchida
- Education and Training Committee, Japanese Society of Pharmaceutical Oncology (JASPO).,Department of Education and Research Center for Pharmacy Practice, Doshisha Women's College of Liberal Arts
| |
Collapse
|
6
|
Mamishin K, Kawasumi K, Tauchi J, Tanaka M, Kaneko A, Iwamoto Y, Matsui R, Yonemura M, Kawasaki T. P79-3 Assessment of medication‘s inquiries for medical safety management via risk classification in outpatient chemotherapy. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.05.516] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
7
|
Goto Y, Nanto M, Oka H, Murakami N, Nakagawa T, Kimura S, Iwamoto Y, Inoue Y, Matsumoto K, Miyamoto J, Hashimoto N. Radiological and clinical features of twig-like middle cerebral artery in comparison with moyamoya angiopathy: a multicenter retrospective study. J Neurosurg 2022; 137:1718-1726. [PMID: 35426829 DOI: 10.3171/2022.2.jns212338] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2021] [Accepted: 02/24/2022] [Indexed: 11/06/2022]
Abstract
OBJECTIVE Twig-like middle cerebral artery (T-MCA) is a rare congenital anomaly that is difficult to distinguish from moyamoya angiopathy (MMA), given the similarity of the angioarchitectures. The aim of this study was to gain insights into the radiological and clinical features of T-MCA and to distinguish this condition from MMA. METHODS A multicenter retrospective study was conducted in 29 patients with T-MCA and 57 patients with MMA. Demographic, radiological, and clinical data were compared between the patients with T-MCA and those with MMA. RESULTS The T-MCA group tended to be older than the MMA group (mean age 47 ± 18 vs 39 ± 22 years). Twenty patients with T-MCA (69%) were initially diagnosed with MMA. All T-MCA cases had twig-like networks and steno-occlusive changes involving the MCA. The T-MCA group had a higher incidence of intracranial aneurysms (35% vs 11%) and coexisting arterial anomalies (48% vs 12%). T-MCA and MMA cases had significant differences in involvement of the internal carotid artery terminus (0% vs 100%) and posterior cerebral artery (0% vs 23%), and in transdural anastomosis (0% vs 51%). T-MCA cases were less likely to present with stroke (59% vs 86%) and more likely to be asymptomatic (28% vs 12%). Of the patients with stroke, those with T-MCA had more hemorrhagic strokes (41% vs 29%) and fewer ischemic strokes (59% vs 71%) compared to those with MMA. CONCLUSIONS This study suggests that T-MCA is a different disease entity from MMA based on significant differences in the radiological and clinical features. Neurosurgeons should recognize this anomaly and understand the key features that differentiate T-MCA from MMA.
Collapse
Affiliation(s)
- Yudai Goto
- 1Department of Neurosurgery, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto.,2Department of Neurosurgery, Kyoto Daiichi Red Cross Hospital, Kyoto
| | - Masataka Nanto
- 1Department of Neurosurgery, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto
| | - Hideki Oka
- 3Department of Neurosurgery, Saiseikai Shigaken Hospital, Ritto
| | | | - Toru Nakagawa
- 5Department of Neurosurgery, Saiseikai Suita Hospital, Suita
| | - Satoshi Kimura
- 2Department of Neurosurgery, Kyoto Daiichi Red Cross Hospital, Kyoto
| | - Yoshihiro Iwamoto
- 6Department of Neurosurgery, Kyoto Yamashiro General Medical Center, Kizugawa
| | - Yasuo Inoue
- 7Department of Neurosurgery, Maizuru Medical Center, Maizuru
| | - Keigo Matsumoto
- 8Department of Neurosurgery, JCHO Kobe Central Hospital, Kobe; and
| | - Junichi Miyamoto
- 9Department of Neurosurgery, Saiseikai Kyoto Hospital, Nagaokakyo, Japan
| | - Naoya Hashimoto
- 1Department of Neurosurgery, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto
| |
Collapse
|
8
|
Tanizaki J, Yonemori K, Akiyoshi K, Minami H, Ueda H, Takiguchi Y, Miura Y, Segawa Y, Takahashi S, Iwamoto Y, Kidera Y, Fukuoka K, Ito A, Chiba Y, Sakai K, Nishio K, Nakagawa K, Hayashi H. Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary. Ann Oncol 2021; 33:216-226. [PMID: 34843940 DOI: 10.1016/j.annonc.2021.11.009] [Citation(s) in RCA: 23] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2021] [Revised: 10/31/2021] [Accepted: 11/21/2021] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND Cancer of unknown primary (CUP) has a poor prognosis. Given the recent approval of immune checkpoint inhibitors for several cancer types, we carried out a multicenter phase II study to assess the efficacy of nivolumab for patients with CUP. PATIENTS AND METHODS Patients with CUP who were previously treated with at least one line of systemic chemotherapy constituted the principal study population. Previously untreated patients with CUP were also enrolled for exploratory analysis. Nivolumab (240 mg/body) was administered every 2 weeks for up to 52 cycles. The primary endpoint was objective response rate in previously treated patients as determined by blinded independent central review according to RECIST version 1.1. RESULTS Fifty-six patients with CUP were enrolled in the trial. For the 45 previously treated patients, objective response rate was 22.2% [95% confidence interval (CI), 11.2% to 37.1%], with a median progression-free survival and overall survival of 4.0 months (95% CI, 1.9-5.8 months) and 15.9 months (95% CI, 8.4-21.5 months), respectively. Similar clinical benefits were also observed in the 11 previously untreated patients. Better clinical efficacy of nivolumab was apparent for tumors with a higher programmed death-ligand 1 expression level, for those with a higher tumor mutation burden, and for microsatellite instability-high tumors. In contrast, no differences in efficacy were apparent between tumor subgroups based on estimated tissue of origin. Adverse events were consistent with the known safety profile of nivolumab. No treatment-related death was observed. CONCLUSIONS Our results demonstrate a clinical benefit of nivolumab for patients with CUP, suggesting that nivolumab is a potential additional therapeutic option for CUP.
Collapse
Affiliation(s)
- J Tanizaki
- Department of Medical Oncology, Kindai University Faculty of Medicine, Osakasayama, Japan
| | - K Yonemori
- Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
| | - K Akiyoshi
- Department of Medical Oncology, Osaka City General Hospital, Osaka, Japan
| | - H Minami
- Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan
| | - H Ueda
- Respiratory Medicine and Medical Oncology, Wakayama Medical University, Wakayama, Japan
| | - Y Takiguchi
- Department of Medical Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - Y Miura
- Department of Medical Oncology, Toranomon Hospital, Tokyo, Japan
| | - Y Segawa
- Department of Medical Oncology, International Medical Center, Saitama Medical University, Hidaka, Japan
| | - S Takahashi
- Department of Medical Oncology, Tohoku University Hospital, Sendai, Japan
| | - Y Iwamoto
- Department of Medical Oncology, Hiroshima City Hospital Organization, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan
| | - Y Kidera
- Clinical Research Center, Kindai University Hospital, Osakasayama, Japan
| | - K Fukuoka
- Clinical Research Center, Kindai University Hospital, Osakasayama, Japan
| | - A Ito
- Department ofPathology, Kindai University Faculty of Medicine, Osakasayama, Japan
| | - Y Chiba
- Clinical Research Center, Kindai University Hospital, Osakasayama, Japan
| | - K Sakai
- Department of Genome Biology, Kindai University Faculty of Medicine, Osakasayama, Japan
| | - K Nishio
- Department of Genome Biology, Kindai University Faculty of Medicine, Osakasayama, Japan
| | - K Nakagawa
- Department of Medical Oncology, Kindai University Faculty of Medicine, Osakasayama, Japan
| | - H Hayashi
- Department of Medical Oncology, Kindai University Faculty of Medicine, Osakasayama, Japan.
| |
Collapse
|
9
|
Tsuchiya M, Terazono H, Maki Y, Yoshikawa N, Kawahara Y, Nishimura K, Shinohara K, Ogawa D, Mori R, Iwamoto Y, Itagaki F, Masuko H, Yonemura M, Uchida M. Evaluation of a web-based educational programme for pharmacists during the COVID-19 pandemic in Japan. J Clin Pharm Ther 2021; 46:1743-1749. [PMID: 34480777 PMCID: PMC8657323 DOI: 10.1111/jcpt.13526] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2021] [Accepted: 08/26/2021] [Indexed: 12/01/2022]
Abstract
WHAT IS KNOWN AND OBJECTIVE Continuing education is essential for pharmacists to acquire and maintain the knowledge, skills, and ethical attitudes necessary for clinical practice. However, with the emergence of COVID-19, the social circumstances and face-to-face learning environments have changed. The objectives of this study were to determine Japanese pharmacists' perception of a web-based educational programme in oncology, and assess changes in their understanding of pharmaceutical care in oncology before and after their participation in the webinar. METHODS Questionnaire-based surveys were conducted for the participants of the web-based educational programme to determine their perspectives on the webinar, and their degree of comprehension of the five cancer types covered before and after watching the webinar. RESULTS AND DISCUSSION Of the 1936 pharmacists taking the programme, all participated in the pre-webinar survey, and 1861 (96.1%) in the post-webinar survey. Compared with previous seminars that were held in the offline mode before the COVID-19 pandemic, 76.8% of respondents were significantly satisfied with the web-based educational programme. The median post-webinar comprehension scores in all modules were significantly higher than the median pre-webinar scores (p < 0.0001). A majority of the participants agreed that a web-based educational programme was satisfactory in acquiring knowledge. WHAT IS NEW AND CONCLUSION This web-based educational programme was effective for Japanese pharmacists for postgraduate education in pharmaceutical care in oncology. To the best of our knowledge, our study is the first to report the effectiveness of a web-based educational programme for oncology pharmacists using a large population.
Collapse
Affiliation(s)
- Masami Tsuchiya
- Department of Pharmacy, Miyagi Cancer Center, Natori, Japan.,Education and Training Committee, Japanese Society of Pharmaceutical Oncology (JASPO), Chuo-ku, Japan
| | - Hideyuki Terazono
- Education and Training Committee, Japanese Society of Pharmaceutical Oncology (JASPO), Chuo-ku, Japan.,Department of Pharmacy, Kagoshima University Hospital, Kagoshima, Japan
| | - Yosuke Maki
- Education and Training Committee, Japanese Society of Pharmaceutical Oncology (JASPO), Chuo-ku, Japan.,Department of Pharmacy, Nagasaki Medical Center, Omura, Japan
| | - Naoki Yoshikawa
- Education and Training Committee, Japanese Society of Pharmaceutical Oncology (JASPO), Chuo-ku, Japan.,Department of Pharmacy, University of Miyazaki Hospital, Miyazaki, Japan
| | - Yosuke Kawahara
- Education and Training Committee, Japanese Society of Pharmaceutical Oncology (JASPO), Chuo-ku, Japan.,Department of Pharmacy, JR Tokyo General Hospital, Shibuya-ku, Japan
| | - Keiko Nishimura
- Education and Training Committee, Japanese Society of Pharmaceutical Oncology (JASPO), Chuo-ku, Japan.,Sogo Medical, Fukuoka, Japan
| | - Keisuke Shinohara
- Education and Training Committee, Japanese Society of Pharmaceutical Oncology (JASPO), Chuo-ku, Japan.,Department of Pharmacy, Saku Central Hospital Advanced Care Center, Saku, Japan
| | - Daisuke Ogawa
- Education and Training Committee, Japanese Society of Pharmaceutical Oncology (JASPO), Chuo-ku, Japan.,Department of Pharmacy, Matsuda Hospital, Kurashiki, Japan
| | - Riho Mori
- Education and Training Committee, Japanese Society of Pharmaceutical Oncology (JASPO), Chuo-ku, Japan.,Department of Pharmacy, Tokusima Municipal Hospital, Tokushima, Japan
| | - Yoshihiro Iwamoto
- Education and Training Committee, Japanese Society of Pharmaceutical Oncology (JASPO), Chuo-ku, Japan.,Department of Pharmacy, National Cancer Center Hospital East, Kashiwa, Japan
| | - Fumio Itagaki
- Education and Training Committee, Japanese Society of Pharmaceutical Oncology (JASPO), Chuo-ku, Japan.,Department of Clinical & Pharmaceutical Sciences, Faculty of Pharma Sciences, Teikyo University, Itabashi-ku, Japan
| | - Hiroyuki Masuko
- Education and Training Committee, Japanese Society of Pharmaceutical Oncology (JASPO), Chuo-ku, Japan.,Department of Pharmacy, Hokkaido Medical Center for Child Health and Rehabilitation, Sapporo, Japan
| | - Masahito Yonemura
- Education and Training Committee, Japanese Society of Pharmaceutical Oncology (JASPO), Chuo-ku, Japan.,Department of Pharmacy, National Cancer Center Hospital East, Kashiwa, Japan
| | - Mayako Uchida
- Education and Training Committee, Japanese Society of Pharmaceutical Oncology (JASPO), Chuo-ku, Japan.,Department of Education and Research Center for Pharmacy Practice, Doshisha Women's College of Liberal Arts, Kyotanabe, Japan
| |
Collapse
|
10
|
Iwamoto Y, Seki Y, Taya K, Tanaka M, Iriguchi S, Miyake Y, Nakayama EE, Miura T, Shioda T, Akari H, Takaori-Kondo A, Kaneko S. Generation of macrophages with altered viral sensitivity from genome-edited rhesus macaque iPSCs to model human disease. Mol Ther Methods Clin Dev 2021; 21:262-273. [PMID: 33869654 PMCID: PMC8039773 DOI: 10.1016/j.omtm.2021.03.008] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/28/2020] [Accepted: 03/11/2021] [Indexed: 01/14/2023]
Abstract
Because of their close biological similarity to humans, non-human primate (NHP) models are very useful for the development of induced pluripotent stem cell (iPSC)-based cell and regenerative organ transplantation therapies. However, knowledge on the establishment, differentiation, and genetic modification of NHP-iPSCs, especially rhesus macaque iPSCs, is limited. We succeeded in establishing iPSCs from the peripheral blood of rhesus macaques (Rh-iPSCs) by combining the Yamanaka reprograming factors and two inhibitors (GSK-3 inhibitor [CHIR 99021] and MEK1/2 inhibitor [PD0325901]) and differentiated the cells into functional macrophages through hematopoietic progenitor cells. To confirm feasibility of the Rh-iPSC-derived macrophages as a platform for bioassays to model diseases, we knocked out TRIM5 gene in Rh-iPSCs by CRISPR-Cas9, which is a species-specific HIV resistance factor. TRIM5 knockout (KO) iPSCs had the same differentiation potential to macrophages as did Rh-iPSCs, but the differentiated macrophages showed a gain of sensitivity to HIV infection in vitro. Our reprogramming, gene editing, and differentiation protocols used to obtain Rh-iPSC-derived macrophages can be applied to other gene mutations, expanding the number of NHP gene therapy models.
Collapse
Affiliation(s)
- Yoshihiro Iwamoto
- Shin Kaneko Laboratory, Department of Cell Growth and Development, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan.,Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Yohei Seki
- Center for Human Evolution Modeling Research, Primate Research Institute, Kyoto University, Kyoto, Japan
| | - Kahoru Taya
- Shin Kaneko Laboratory, Department of Cell Growth and Development, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan.,Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
| | - Masahiro Tanaka
- Shin Kaneko Laboratory, Department of Cell Growth and Development, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan
| | - Shoichi Iriguchi
- Shin Kaneko Laboratory, Department of Cell Growth and Development, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan
| | - Yasuyuki Miyake
- Shin Kaneko Laboratory, Department of Cell Growth and Development, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan
| | - Emi E Nakayama
- Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
| | - Tomoyuki Miura
- Laboratory of Primate Model, Research Center for Infectious Diseases, Institute for Frontier Life and Medical Science, Kyoto University, Kyoto, Japan
| | - Tatsuo Shioda
- Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
| | - Hirofumi Akari
- Center for Human Evolution Modeling Research, Primate Research Institute, Kyoto University, Kyoto, Japan.,Laboratory of Infectious Disease Model, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto, Japan
| | - Akifumi Takaori-Kondo
- Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Shin Kaneko
- Shin Kaneko Laboratory, Department of Cell Growth and Development, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan
| |
Collapse
|
11
|
Sazali N, Salleh W, Ismail A, Ismail N, Mohamed MA, Nordin N, Sokri M, Iwamoto Y, Honda S. Retraction notice to “Enhanced gas separation performance using carbon membranes containing nanocrystalline cellulose and BTDA-TDI/MDI polyimide” [Chem. Eng. Res. Des. 140 (2018) 221–228]. Chem Eng Res Des 2020. [DOI: 10.1016/j.cherd.2020.08.030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
12
|
Abstract
Optical grade Dy2O3 ceramics was successfully produced by adding a small amount of ZrO2 as a sintering aid and hot isostatic pressing treatment at 1500∘C after pre-sintering at 1550∘C. No residual pores, grain boundary phases, or second phases were detected inside the transparent ceramics. Since birefringence was not observed under the polarizer, the produced Dy2O3 ceramics is an optically isotropic body. There was almost no beam distortion during the laser irradiation test, and the optical loss was extremely small (<0.1%/cm). The Verdet constant was 422radT-1m-1 at a wavelength of 633 nm, and the extinction ratio was 34 dB.
Collapse
|
13
|
Tsuboi M, Zenke Y, Chiba Y, Satouchi M, Mitsuoka S, Shimizu J, Daga H, Fujimoto D, Mori M, Aoki T, Sawa T, Omori S, Saka H, Iwamoto Y, Okuno M, Hirashima T, Kashiwabara K, Tachihara M, Yamamoto N, Nakagawa K. Histological type analysis of 10-year follow-up of WJTOG0105: A phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz436.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
14
|
Zenke Y, Tsuboi M, Chiba Y, Satouchi M, Mitsuoka S, Shimizu J, Daga H, Fujimoto D, Mori M, Aoki T, Sawa T, Omori S, Saka H, Iwamoto Y, Okuno M, Hirashima T, Kshiwabara K, Tachihara M, Yamamoto N, Nakagawa K. Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small cell lung cancer: 10-year follow-up of West Japan thoracic oncology group WJTOG0105. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz259.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
15
|
Tanaka K, Morita S, Ando M, Yokoyama T, Nakamura A, Yoshioka H, Ishiguro T, Miura S, Toyozawa R, Oguri T, Daga H, Ko R, Bessho A, Tachihara M, Iwamoto Y, Hirano K, Nakanishi Y, Nakagawa K, Yamamoto N, Okamoto I. MA13.06 Ph3 Study of Maintenance Therapy with S-1 vs BSC After Induction Therapy with Carboplatin + S-1 for Advanced Squamous Cell Lung Cancer (WJOG7512L). J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.605] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
16
|
Sazali N, Salleh W, Ismail A, Ismail N, Azuwa Mohamed M, Nordin N, Sokri M, Iwamoto Y, Honda S. RETRACTED: Enhanced gas separation performance using carbon membranes containing nanocrystalline cellulose and BTDA-TDI/MDI polyimide. Chem Eng Res Des 2018. [DOI: 10.1016/j.cherd.2018.09.039] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
17
|
Urakawa H, Mizusawa J, Tanaka K, Eba J, Hiraga H, Hosaka M, Kawai A, Nakatani F, Kobayashi E, Nishida Y, Okamoto T, Matsunobu T, Iwamoto Y, Fukuda H, Ozaki T. A randomized phase III study of denosumab before curettage for giant cell tumor of bone: Japan Clinical Oncology Group study JCOG1610. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy299.057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
18
|
Sazali N, Salleh WNW, Ismail AF, Wong KC, Iwamoto Y. Exploiting pyrolysis protocols on BTDA-TDI/MDI (P84) polyimide/nanocrystalline cellulose carbon membrane for gas separations. J Appl Polym Sci 2018. [DOI: 10.1002/app.46901] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- N. Sazali
- Advanced Membrane Technology Research Centre (AMTEC); Universiti Teknologi Malaysia; 81310 Skudai Johor Darul Takzim Malaysia
- Faculty of Chemical and Energy Engineering (FCEE); Universiti Teknologi Malaysia; 81310 Skudai Johor Darul Takzim Malaysia
| | - W. N. W. Salleh
- Advanced Membrane Technology Research Centre (AMTEC); Universiti Teknologi Malaysia; 81310 Skudai Johor Darul Takzim Malaysia
- Faculty of Chemical and Energy Engineering (FCEE); Universiti Teknologi Malaysia; 81310 Skudai Johor Darul Takzim Malaysia
| | - A. F. Ismail
- Advanced Membrane Technology Research Centre (AMTEC); Universiti Teknologi Malaysia; 81310 Skudai Johor Darul Takzim Malaysia
- Faculty of Chemical and Energy Engineering (FCEE); Universiti Teknologi Malaysia; 81310 Skudai Johor Darul Takzim Malaysia
| | - K. C. Wong
- Advanced Membrane Technology Research Centre (AMTEC); Universiti Teknologi Malaysia; 81310 Skudai Johor Darul Takzim Malaysia
- Faculty of Chemical and Energy Engineering (FCEE); Universiti Teknologi Malaysia; 81310 Skudai Johor Darul Takzim Malaysia
| | - Y. Iwamoto
- Department of Frontier Materials, Graduate School of Engineering; Nagoya Institute of Technology; Gokiso-cho, Showa-ku, 466-555 Nagoya Japan
| |
Collapse
|
19
|
Yoshioka H, Katakami N, Okamoto H, Iwamoto Y, Seto T, Takahashi T, Sunaga N, Kudoh S, Chikamori K, Harada M, Tanaka H, Saito H, Saka H, Takeda K, Nogami N, Masuda N, Harada T, Kitagawa H, Horio H, Yamanaka T, Fukuoka M, Yamamoto N, Nakagawa K. A randomized, open-label, phase III trial comparing amrubicin versus docetaxel in patients with previously treated non-small-cell lung cancer. Ann Oncol 2017; 28:285-291. [PMID: 28426104 DOI: 10.1093/annonc/mdw621] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Background Amrubicin is approved for treating non-small-cell lung cancer (NSCLC) and small-cell lung cancer. However, no direct comparisons between amrubicin and docetaxel, a standard treatment for NSCLC, have been reported. Patients and methods We conducted a randomized phase III trial of Japanese NSCLC patients after one or two chemotherapy regimens. Patients were randomized to amrubicin (35 mg/m2 on days 1-3 every 3 weeks) or docetaxel (60 mg/m2 on day 1 every 3 weeks). Outcomes included progression-free survival, overall survival, tumor responses, and safety. Results Between October 2010 and June 2012, 202 patients were enrolled across 32 institutions. Median progression-free survival (3.6 versus 3.0 months; P = 0.54) and overall survival (14.6 versus 13.5 months; P = 0.86) were comparable in the amrubicin and docetaxel groups, respectively. The overall response rate was 14.4% (14/97) and 19.6% (19/97) in the amrubicin and docetaxel groups, respectively (P = 0.45). The disease control rate was 55.7% in both groups. Adverse events occurred in all patients, and included grade ≥3 neutropenia occurred in 82.7% and 78.8% of patients in the amrubicin and docetaxel groups, respectively, grade ≥3 leukopenia occurred in 63.3% and 70.7%, and grade ≥3 febrile neutropenia occurred in 13.3% and 18.2% of patients in the amrubicin and docetaxel groups, respectively. Of eight cardiac-related events in the amrubicin group, three were considered related to amrubicin and resolved without treatment discontinuation. Conclusions This was the first phase III study to compare amrubicin and docetaxel in patients with pretreated NSCLC. Amrubicin did not significantly improve the primary endpoint of PFS compared with docetaxel. Clinical trial registration NCT01207011 (ClinicalTrials.gov).
Collapse
Affiliation(s)
- H Yoshioka
- Department of Respiratory Medicine, Kurashiki Central Hospital, Okayama
| | - N Katakami
- Division of Integrated Oncology, Institute of Biomedical Research and Innovation, Hyogo
| | - H Okamoto
- Department of Respiratory Medicine and Medical Oncology, Yokohama Municipal Citizen's Hospital, Kanagawa
| | - Y Iwamoto
- Department of Medical Oncology, Hiroshima City Hiroshima Citizens Hospital, Hiroshima
| | - T Seto
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka
| | - T Takahashi
- Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka
| | - N Sunaga
- Department of Medicine and Molecular Science, Gunma University School of Medicine, Gunma
| | - S Kudoh
- Department of Respiratory Medicine, Osaka City University Hospital, Osaka
| | - K Chikamori
- Department of Respiratory Medicine, National Hospital Organization Yamaguchi-Ube Medical Center, Yamaguchi
| | - M Harada
- Department of Respiratory Medicine, National Hospital Organization Hokkaido Cancer Center, Sapporo
| | - H Tanaka
- Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata
| | - H Saito
- Department of Respiratory Medicine, Aichi Cancer Center Aichi Hospital, Aichi
| | - H Saka
- Respiratory Medicine and Medical Oncology, National Hospital Organization Nagoya Medical Center, Aichi
| | - K Takeda
- Department of Medical Oncology, Osaka City General Hospital, Osaka
| | - N Nogami
- Department of Respiratory Medicine, National Hospital Organization Shikoku Cancer Center, Ehime
| | - N Masuda
- Department of Respiratory Medicine, Kitasato University Hospital, Kanagawa
| | - T Harada
- Center of Respiratory Disease, Japan Community Health Care Organization Hokkaido Hospital, Sapporo
| | - H Kitagawa
- Drug Development Division, Sumitomo Dainippon Pharma. Co, Ltd, Tokyo
| | - H Horio
- Drug Development Division, Sumitomo Dainippon Pharma. Co, Ltd, Tokyo
| | - T Yamanaka
- Department of Biostatistics and Epidemiology, Graduate School of Medicine, Yokohama City University, Kanagawa
| | - M Fukuoka
- Medical Oncology, Izumi Municipal Hospital, Osaka
| | - N Yamamoto
- Third Department of Internal Medicine, Wakayama Medical University Hospital, Wakayama
| | - K Nakagawa
- Department of Medical Oncology, Faculty of Medicine, Kinki University Hospital, Osaka, Japan
| |
Collapse
|
20
|
Mori Y, Suzuki N, Nagasaka T, Tanioka H, Iwamoto Y, Neki Y, Yamatsuji T, Kobayashi M, Nakajima M, Ojima Y, Ikeda S, Kawamoto K, Shinozaki K, Tsuji A, Hinoi T, Yamaguchi Y, Yamashita K, Shimokawa M, Okajima M, Hazama S. Multicenter phase II study of biweekly XELIRI plus bevacizumab as a second-line therapy in patients with metastatic colorectal cancer (JSWOG-C3 study). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx393.047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
21
|
Takeuchi N, Okada T, Kozono N, Shimoto T, Higaki H, Iwamoto Y. Symmetric Peripheral Running Sutures are Superior to Asymmetric Peripheral Running Sutures for Increasing the Tendon Strength in Flexor Tendon Repair. J Hand Surg Asian Pac Vol 2017; 22:208-213. [PMID: 28506161 DOI: 10.1142/s0218810417500265] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
BACKGROUND The fatigue strength of three peripheral suture techniques for flexor tendon repair was compared by cyclic loading of the repairs in the porcine flexor digitorum tendon. METHODS Thirty-six tendons were sutured using only peripheral sutures with 6-0 Nylon. An initial cyclic load of 10 N for 500 cycles was applied and increased by 10 N for an additional 500 cycles at each new load until rupture. RESULTS The fatigue strength of the symmetric running peripheral suture was 85.0% and 144.8% greater than that of the two kinds of the asymmetric running peripheral sutures. CONCLUSIONS Symmetric running sutures can enhance the suture strength and appears to be a useful technique for increasing the strength of the peripheral suture.
Collapse
Affiliation(s)
- N Takeuchi
- * Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University, Japan
| | - T Okada
- * Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University, Japan
| | - N Kozono
- * Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University, Japan
| | - T Shimoto
- † Department of Information and System Engineering, Faculty of Information Engineering, Fukuoka Institute of Technology, Japan
| | - H Higaki
- ‡ Department of Biorobotics, Faculty of Engineering, Kyushu Sangyo University, Fukuoka, Japan
| | - Y Iwamoto
- * Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University, Japan
| |
Collapse
|
22
|
Abstract
We herein report an unusual case of Brodie's abscess of the radius in a child. A 13-year-old boy presented with pain on his right distal forearm. A plain radiograph showed an 8 cm translucent lesion in the distal radius. MRI showed a penumbra sign on the T1-weighted image, hyperintensity on T2-weighted images, and ring enhancement on the contrast-enhanced T1 image. 18F-FDG PET/CT images showed an uptake at the margin of the radius. Curettage and iliac cancellous bone grafting were undertaken for Brodie's abscess. Bacteriological examinations were found to be negative, however, the pathologic diagnosis showed chronic osteomyelitis. Eight months after surgery, the patient was asymptomatic and there was no sign of recurrence of infection. For Brodie's abscess in a child, thorough debridement is mandatory in addition to cancellous bone grafting. Brodie's abscess should be considered in the differential diagnosis of a patient who presents with forearm pain and exhibit the radiolucent osteolytic lesion on simple radiography.
Collapse
Affiliation(s)
- N Takeuchi
- * Departments of Orthopaedic Surgery, Japan
| | | | - T Okada
- * Departments of Orthopaedic Surgery, Japan
| | - M Hanada
- * Departments of Orthopaedic Surgery, Japan.,† Departments of Plastic Surgery, Japan
| | - H Bekki
- * Departments of Orthopaedic Surgery, Japan.,‡ Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Y Iwamoto
- * Departments of Orthopaedic Surgery, Japan
| |
Collapse
|
23
|
Hagiwara M, Iwase H, Kirihara Y, Yashima H, Iwamoto Y, Satoh D, Nakane Y, Nakashima H, Nakamura T, Tamii A, Hatanaka K. Benchmark Experiment of Neutron Penetration through Iron and Concrete Shields for Hundreds-of-MeV Quasi-Monoenergetic Neutrons—II: Measurements of Neutron Spectrum by an Organic Liquid Scintillator. NUCL TECHNOL 2017. [DOI: 10.13182/nt168-304] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- M. Hagiwara
- High Energy Accelerator Research Organization, KEK, Oho1-1 Tsukuba, Ibaraki 305-0801, Japan
| | - H. Iwase
- High Energy Accelerator Research Organization, KEK, Oho1-1 Tsukuba, Ibaraki 305-0801, Japan
| | - Y. Kirihara
- The Graduate University for Advanced Studies, KEK, 1-1 Oho, Tsukuba, Ibaraki 305-0801, Japan
| | - H. Yashima
- Kyoto University, KURRI, Kumatori-cho, Sennan-gun, Osaka 590-0494, Japan
| | - Y. Iwamoto
- Japan Atomic Energy Agency, 2-4 Shirane Shirakata, Tokai-mura, Naka-gun, Ibaraki 319-1195, Japan
| | - D. Satoh
- Japan Atomic Energy Agency, 2-4 Shirane Shirakata, Tokai-mura, Naka-gun, Ibaraki 319-1195, Japan
| | - Y. Nakane
- Japan Atomic Energy Agency, 2-4 Shirane Shirakata, Tokai-mura, Naka-gun, Ibaraki 319-1195, Japan
| | - H. Nakashima
- Japan Atomic Energy Agency, 2-4 Shirane Shirakata, Tokai-mura, Naka-gun, Ibaraki 319-1195, Japan
| | - T. Nakamura
- Shimizu Corporation, Tohoku University, 4-17, Etchujima 3-chome, Koto-ku, Tokyo 135-8530, Japan
| | - A. Tamii
- Osaka University, Research Center of Nuclear Physics, 10-1 Mihogaoka, Ibaraki, Osaka 567-0047, Japan
| | - K. Hatanaka
- Osaka University, Research Center of Nuclear Physics, 10-1 Mihogaoka, Ibaraki, Osaka 567-0047, Japan
| |
Collapse
|
24
|
Yashima H, Iwase H, Hagiwara M, Kirihara Y, Taniguchi S, Yamakawa H, Oishi K, Iwamoto Y, Satoh D, Nakane Y, Nakashima H, Itoga T, Nakao N, Nakamura T, Tamii A, Hatanaka K. Benchmark Experiment of Neutron Penetration through Iron and Concrete Shields for Hundreds-of-MeV Quasi-Monoenergetic Neutrons—I: Measurements of Neutron Spectrum by a Multimoderator Spectrometer. NUCL TECHNOL 2017. [DOI: 10.13182/nt09-a9198] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- H. Yashima
- Kyoto University, Reactor Research Institute, Asashironishi 2-1010, Kumatori-cho, Sennan-gun, Osaka 590-0494, Japan
| | - H. Iwase
- High Energy Accelerator Research Organization, 1-1 Oho, Tsukuba, Ibaraki 305-0801, Japan
| | - M. Hagiwara
- High Energy Accelerator Research Organization, 1-1 Oho, Tsukuba, Ibaraki 305-0801, Japan
| | - Y. Kirihara
- The Graduate University for Advanced Studies, 1-1 Oho, Tsukuba, Ibaraki 305-0801, Japan
| | - S. Taniguchi
- Japan Synchrotron Radiation Research Institute, 1-1-1, Kouto, Sayo-cho, Sayo-gun, Hyogo 679-5198, Japan
| | - H. Yamakawa
- Shimizu Corporation, 3-4-17 Etchujima, Koto-ku, Tokyo 135-8530, Japan
| | - K. Oishi
- Shimizu Corporation, 3-4-17 Etchujima, Koto-ku, Tokyo 135-8530, Japan
| | - Y. Iwamoto
- Japan Atomic Energy Agency, 2-4 Shirane Shirakata, Tokai-mura, Naka-gun, Ibaraki 319-1195, Japan
| | - D. Satoh
- Japan Atomic Energy Agency, 2-4 Shirane Shirakata, Tokai-mura, Naka-gun, Ibaraki 319-1195, Japan
| | - Y. Nakane
- Japan Atomic Energy Agency, 2-4 Shirane Shirakata, Tokai-mura, Naka-gun, Ibaraki 319-1195, Japan
| | - H. Nakashima
- Japan Atomic Energy Agency, 2-4 Shirane Shirakata, Tokai-mura, Naka-gun, Ibaraki 319-1195, Japan
| | - T. Itoga
- Institute of Physical and Chemical Research, 1-1-1, Kouto, Sayo-cho, Sayo-gun, Hyogo 679-5198, Japan
| | | | - T. Nakamura
- Tohoku University, Cyclotron and Radioisotope Center, Shimizu Corporation, Aoba 6-3, Aramaki, Aoba-ku, Sendai, Miyagi 980-8578, Japan
| | - A. Tamii
- Osaka University, Research Center of Nuclear Physics, 10-1 Mihogaoka, Ibaraki, Osaka 567-0047, Japan
| | - K. Hatanaka
- Osaka University, Research Center of Nuclear Physics, 10-1 Mihogaoka, Ibaraki, Osaka 567-0047, Japan
| |
Collapse
|
25
|
Nakashima H, Sakamoto Y, Iwamoto Y, Matsuda N, Kasugai Y, Nakane Y, Masukawa F, Mokhov NV, Leveling AF, Boehnlein DJ, Vaziri K, Sanami T, Matsumura H, Hagiwara M, Iwase H, Kinoshita N, Hirayama H, Oishi K, Nakamura T, Arakawa H, Shigyo N, Ishibashi K, Yashima H, Nakao N, Niita K. Experimental Studies of Shielding and Irradiation Effects at High-Energy Accelerator Facilities. NUCL TECHNOL 2017. [DOI: 10.13182/nt09-a9229] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- H. Nakashima
- Japan Atomic Energy Agency, Shirane Shirakata 2-4, Tokai, Naka, Ibaraki 319-1195, Japan
| | - Y. Sakamoto
- Japan Atomic Energy Agency, Shirane Shirakata 2-4, Tokai, Naka, Ibaraki 319-1195, Japan
| | - Y. Iwamoto
- Japan Atomic Energy Agency, Shirane Shirakata 2-4, Tokai, Naka, Ibaraki 319-1195, Japan
| | - N. Matsuda
- Japan Atomic Energy Agency, Shirane Shirakata 2-4, Tokai, Naka, Ibaraki 319-1195, Japan
| | - Y. Kasugai
- Japan Atomic Energy Agency, Shirane Shirakata 2-4, Tokai, Naka, Ibaraki 319-1195, Japan
| | - Y. Nakane
- Japan Atomic Energy Agency, Shirane Shirakata 2-4, Tokai, Naka, Ibaraki 319-1195, Japan
| | - F. Masukawa
- Japan Atomic Energy Agency, Shirane Shirakata 2-4, Tokai, Naka, Ibaraki 319-1195, Japan
| | - N. V. Mokhov
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510-5011
| | - A. F. Leveling
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510-5011
| | - D. J. Boehnlein
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510-5011
| | - K. Vaziri
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510-5011
| | - T. Sanami
- High Energy Accelerator Research Organization, Oho1-1, Tsukuba 305-0801, Japan
| | - H. Matsumura
- High Energy Accelerator Research Organization, Oho1-1, Tsukuba 305-0801, Japan
| | - M. Hagiwara
- High Energy Accelerator Research Organization, Oho1-1, Tsukuba 305-0801, Japan
| | - H. Iwase
- High Energy Accelerator Research Organization, Oho1-1, Tsukuba 305-0801, Japan
| | - N. Kinoshita
- High Energy Accelerator Research Organization, Oho1-1, Tsukuba 305-0801, Japan
| | - H. Hirayama
- High Energy Accelerator Research Organization, Oho1-1, Tsukuba 305-0801, Japan
| | - K. Oishi
- Shimizu Corporation, Etchujima 3-4-17, Koto, Tokyo 135-8530, Japan
| | - T. Nakamura
- Tohuku University, Aramaki, Aoba, Sendai 980-8578, Japan
| | - H. Arakawa
- Kyushu University, Motooka 744, Nishi, Fukuoka 819-0395, Japan
| | - N. Shigyo
- Kyushu University, Motooka 744, Nishi, Fukuoka 819-0395, Japan
| | - K. Ishibashi
- Kyushu University, Motooka 744, Nishi, Fukuoka 819-0395, Japan
| | - H. Yashima
- Kyoto University, Reactor Research Institute, Asashironishi 2-1010, Kumatori, Sennan Osaka 590-0494, Japan
| | | | - K. Niita
- Research Organization for Information Science & Technology, Shirakata Shirane 2-4, Tokai, Naka Ibaraki 319-1106, Japan
| |
Collapse
|
26
|
Mawatari T, Muraoka R, Iwamoto Y. Relationship between baseline characteristics and response to risedronate treatment for osteoporosis: data from three Japanese phase III trials. Osteoporos Int 2017; 28:1279-1286. [PMID: 27900428 PMCID: PMC5357292 DOI: 10.1007/s00198-016-3848-4] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/18/2016] [Accepted: 11/17/2016] [Indexed: 10/25/2022]
Abstract
UNLABELLED We evaluated the influence of baseline age, bone mineral density (BMD), and serum levels of vitamin D on the response to risedronate treatment. Risedronate consistently increased BMD, but our results suggest vitamin D supplementation may be necessary to achieve optimal treatment effect. Furthermore, early intervention may help prevent bone fractures. INTRODUCTION We aimed to investigate the influence of baseline age, BMD, and vitamin D insufficiency on the response to risedronate treatment. METHODS Data regarding 1447 patients was obtained from the registries of three phase III clinical trials of risedronate. The response to treatment was expressed in terms of BMD increase and occurrence of new vertebral fractures. The patients were stratified by baseline values for age (<65, 65-72, and ≥72 years), lumbar spine BMD T-score (osteoporotic, <-2.5; and non-osteoporotic, ≥- 2.5), and serum levels of 25-hydroxyvitamin D (deficient, <21 ng/mL; and non-deficient, ≥21 ng/mL). RESULTS Risedronate consistently increased lumbar spine BMD in all the groups, with similar percentage and absolute increments in all the age tertiles. The percentage, but not absolute, increment in BMD was significantly higher (p = 0.0003) in the osteoporotic than that in the non-osteoporotic patients (baseline). Of the 1330 patients whose baseline serum levels of 25-hydroxyvitamin D were available, 44.7% had vitamin D deficiency (<20 ng/mL), while 89.2% had insufficiency (<30 ng/mL). The percentage and absolute increments in BMD were lower (p < 0.05 and p < 0.01, respectively) in the vitamin D-deficient than those in the non-deficient patients. New vertebral fractures occurred in 1.5 and 0.8% of the osteoporotic and non-osteoporotic patients, respectively (end of the treatment). CONCLUSIONS Therapeutic response in elderly patients is consistent, but early initiation of risedronate treatment may help prevent fractures. Risedronate-induced increase in BMD is lower in patients with vitamin D deficiency, suggesting that vitamin D supplementation is important to achieve optimal treatment response.
Collapse
Affiliation(s)
- T Mawatari
- Department of Orthopaedic Surgery, Hamanomachi Hospital, Fukuoka, Japan.
- Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
| | - R Muraoka
- Data Science Group, Clinical Development Department, EA Pharma Co., Ltd., Tokyo, Japan
| | - Y Iwamoto
- Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
- Department of Orthopaedic Surgery, Kyushu Rosai Hospital, Fukuoka, Japan
| |
Collapse
|
27
|
Sumida S, Ichimura M, Yokoyama T, Hirata M, Ikezoe R, Iwamoto Y, Okada T, Takeyama K, Jang S, Sakamoto M, Nakashima Y, Yoshikawa M, Minami R, Oki K, Mizuguchi M, Ichimura K. High-Density Plasma Production in the GAMMA 10 Central Cell with ICRF Heating on Both Anchor Cells. Fusion Science and Technology 2017. [DOI: 10.13182/fst14-890] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- S. Sumida
- University of Tsukuba, Plasma Research Center, Tsukuba, Japan
| | - M. Ichimura
- University of Tsukuba, Plasma Research Center, Tsukuba, Japan
| | - T. Yokoyama
- University of Tsukuba, Plasma Research Center, Tsukuba, Japan
| | - M. Hirata
- University of Tsukuba, Plasma Research Center, Tsukuba, Japan
| | - R. Ikezoe
- University of Tsukuba, Plasma Research Center, Tsukuba, Japan
| | - Y. Iwamoto
- University of Tsukuba, Plasma Research Center, Tsukuba, Japan
| | - T. Okada
- University of Tsukuba, Plasma Research Center, Tsukuba, Japan
| | - K. Takeyama
- University of Tsukuba, Plasma Research Center, Tsukuba, Japan
| | - S. Jang
- University of Tsukuba, Plasma Research Center, Tsukuba, Japan
| | - M. Sakamoto
- University of Tsukuba, Plasma Research Center, Tsukuba, Japan
| | - Y. Nakashima
- University of Tsukuba, Plasma Research Center, Tsukuba, Japan
| | - M. Yoshikawa
- University of Tsukuba, Plasma Research Center, Tsukuba, Japan
| | - R. Minami
- University of Tsukuba, Plasma Research Center, Tsukuba, Japan
| | - K. Oki
- University of Tsukuba, Plasma Research Center, Tsukuba, Japan
| | - M. Mizuguchi
- University of Tsukuba, Plasma Research Center, Tsukuba, Japan
| | - K. Ichimura
- University of Tsukuba, Plasma Research Center, Tsukuba, Japan
| |
Collapse
|
28
|
Ikezoe R, Ichimura M, Hirata M, Yokoyama T, Iwamoto Y, Okada T, Sumida S, Takeyama K, Jang S, Oi T, Ichimura K, Nakashima Y. Extension of Operational Regimes with ICRF Heating on GAMMA 10/PDX. Fusion Science and Technology 2017. [DOI: 10.13182/fst14-853] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- R. Ikezoe
- University of Tsukuba, Plasma Research Center, Tsukuba, Japan
| | - M. Ichimura
- University of Tsukuba, Plasma Research Center, Tsukuba, Japan
| | - M. Hirata
- University of Tsukuba, Plasma Research Center, Tsukuba, Japan
| | - T. Yokoyama
- University of Tsukuba, Plasma Research Center, Tsukuba, Japan
| | - Y. Iwamoto
- University of Tsukuba, Plasma Research Center, Tsukuba, Japan
| | - T. Okada
- University of Tsukuba, Plasma Research Center, Tsukuba, Japan
| | - S. Sumida
- University of Tsukuba, Plasma Research Center, Tsukuba, Japan
| | - K. Takeyama
- University of Tsukuba, Plasma Research Center, Tsukuba, Japan
| | - S. Jang
- University of Tsukuba, Plasma Research Center, Tsukuba, Japan
| | - T. Oi
- University of Tsukuba, Plasma Research Center, Tsukuba, Japan
| | - K. Ichimura
- University of Tsukuba, Plasma Research Center, Tsukuba, Japan
| | - Y. Nakashima
- University of Tsukuba, Plasma Research Center, Tsukuba, Japan
| |
Collapse
|
29
|
Yokoyama T, Ichimura M, Fukuyama A, Sumida S, Hirata M, Ikezoe R, Iwamoto Y, Okada T, Takeyama K, Jang S. Analysis of Wave Excitation of the Phase-Control ICRF Antennas with Three-Dimensional Full Wave Code on GAMMA 10. Fusion Science and Technology 2017. [DOI: 10.13182/fst14-899] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- T. Yokoyama
- University of Tsukuba, Plasma Research Center, Tsukuba, Japan
| | - M. Ichimura
- University of Tsukuba, Plasma Research Center, Tsukuba, Japan
| | - A. Fukuyama
- Kyoto University, Graduate School of Engineering, Department of Nuclear Engineering, Kyoto, Japan
| | - S. Sumida
- University of Tsukuba, Plasma Research Center, Tsukuba, Japan
| | - M. Hirata
- University of Tsukuba, Plasma Research Center, Tsukuba, Japan
| | - R. Ikezoe
- University of Tsukuba, Plasma Research Center, Tsukuba, Japan
| | - Y. Iwamoto
- University of Tsukuba, Plasma Research Center, Tsukuba, Japan
| | - T. Okada
- University of Tsukuba, Plasma Research Center, Tsukuba, Japan
| | - K. Takeyama
- University of Tsukuba, Plasma Research Center, Tsukuba, Japan
| | - S. Jang
- University of Tsukuba, Plasma Research Center, Tsukuba, Japan
| |
Collapse
|
30
|
Theis C, Carbonez P, Feldbaumer E, Forkel-Wirth D, Jaegerhofer L, Pangallo M, Perrin D, Urscheler C, Roesler S, Vincke H, Widorski M, Iwamoto Y, Hagiwara M, Satoh D, Iwase H, Yashima H, Matsumoto T, Masuda A, Nishiyama J, Harano H, Itoga T, Nakamura T, Sato T, Nakane Y, Nakashima H, Sakamoto Y, Taniguchi S, Nakao N, Tamii A, Shima T, Hatanaka K. Characterization of the PTW 34031 ionization chamber (PMI) at RCNP with high energy neutrons ranging from 100 – 392 MeV. EPJ Web Conf 2017. [DOI: 10.1051/epjconf/201715308018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
31
|
Daiko Y, Schmidt J, Kawamura G, Romeis S, Segets D, Iwamoto Y, Peukert W. Mechanochemically induced sulfur doping in ZnO via oxygen vacancy formation. Phys Chem Chem Phys 2017; 19:13838-13845. [DOI: 10.1039/c7cp01489a] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Mechanochemically induced oxygen vacancy of ZnO is indispensable in order to control the level of sulfur doping quantitatively.
Collapse
Affiliation(s)
- Y. Daiko
- Department of Life Science and Applied Chemistry
- Nagoya Institute of Technology
- Nagoya
- Japan
| | - J. Schmidt
- Institute of Particle Technology (LFG)
- Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)
- Erlangen
- Germany
- Interdisciplinary Center for Functional Particle Systems (FPS)
| | - G. Kawamura
- Department of Electrical and Electronic Information Engineering
- Toyohashi University of Technology
- Toyohashi
- Japan
| | - S. Romeis
- Institute of Particle Technology (LFG)
- Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)
- Erlangen
- Germany
- Interdisciplinary Center for Functional Particle Systems (FPS)
| | - D. Segets
- Institute of Particle Technology (LFG)
- Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)
- Erlangen
- Germany
- Interdisciplinary Center for Functional Particle Systems (FPS)
| | - Y. Iwamoto
- Department of Life Science and Applied Chemistry
- Nagoya Institute of Technology
- Nagoya
- Japan
| | - W. Peukert
- Institute of Particle Technology (LFG)
- Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)
- Erlangen
- Germany
- Interdisciplinary Center for Functional Particle Systems (FPS)
| |
Collapse
|
32
|
Kozono N, Okada T, Takeuchi N, Hanada M, Shimoto T, Iwamoto Y. Asymmetric six-strand core sutures enhance tendon fatigue strength and the optimal asymmetry. J Hand Surg Eur Vol 2016; 41:802-8. [PMID: 26896454 DOI: 10.1177/1753193416631454] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/19/2015] [Accepted: 09/30/2015] [Indexed: 02/03/2023]
Abstract
Under cyclic loading, we recorded the fatigue strength of a six-strand tendon repair with different symmetry in the lengths of suture purchase in two stumps of 120 dental rolls and in 30 porcine tendons. First, the strengths of the repairs with 1, 2, 3, 4 and 5 mm asymmetry were screened using the dental rolls. The asymmetric core suture repairs were then made with a Kessler repair of equal suture purchase (10 mm) in two tendon stumps, and shifting two other Kessler repairs by 1, 3 or 5 mm, respectively, along the longitudinal axis of the tendon in relation to the first (symmetric) Kessler repair. The core repairs with 3 mm or more asymmetry in suture purchases in two tendon ends showed significantly greater fatigue strength and significantly smaller gaps compared with 1 mm asymmetry in core suture repair. Our results support that asymmetric placement of core sutures in two tendon ends favour resisting gapping at the repair site and 3 mm or more asymmetry is needed to produce such beneficial effects.
Collapse
Affiliation(s)
- N Kozono
- Department of Orthopaedic Surgery, Kyushu University, Fukuoka, Japan
| | - T Okada
- Department of Orthopaedic Surgery, Kyushu University, Fukuoka, Japan
| | - N Takeuchi
- Department of Orthopaedic Surgery, Kyushu University, Fukuoka, Japan
| | - M Hanada
- Department of Orthopaedic Surgery, Kyushu University, Fukuoka, Japan Department of Plastic Surgery, Kyushu University, Fukuoka, Japan
| | - T Shimoto
- Department of Information and System Engineering, Fukuoka Institute of Technology, Fukuoka, Japan
| | - Y Iwamoto
- Department of Orthopaedic Surgery, Kyushu University, Fukuoka, Japan
| |
Collapse
|
33
|
Makino H, Haneda M, Babazono T, Moriya T, Ito S, Iwamoto Y, Kawamori R, Takeuchi M, Katayama S. The Telmisartan Renoprotective Study from Incipient Nephropathy to Overt Nephropathy – Rationale, Study Design, Treatment Plan and Baseline Characteristics of the Incipient to Overt: Angiotensin II Receptor Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) Study. J Int Med Res 2016; 33:677-86. [PMID: 16372586 DOI: 10.1177/147323000503300610] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
We planned the INNOVATION study to determine whether telmisartan, an angiotensin-2-receptor blocker, delays the progression of renal disease from incipient nephropathy to overt nephropathy in hypertensive or normotensive Japanese patients with type 2 diabetes mellitus. The INNOVATION study is a randomized, double-blind, placebo-controlled trial. Eligible patients must have incipient nephropathy (defined as a urinary albumin to creatinine ratio of 100-300 mg/g creatinine) and a serum creatinine concentration of < 1.5 mg/dl for men and < 1.3 mg/dl for women. Patients who need treatment with angiotensin II receptor blockers or angiotensin-converting enzyme inhibitors are excluded. Eligible patients are randomly assigned to three groups: telmisartan titrated to 40 mg; telmisartan titrated to 80 mg; or placebo. The primary endpoint is the time from baseline visit to first detection of overt nephropathy (defined by a urinary albumin to creatinine ratio that is > 300 mg/g creatinine and 30% higher than the baseline on at least two consecutive visits). A total of 1855 patients have been enrolled from 160 study centres. In 527 randomized patients (28.4% of the enrolled patients), mean (SD) urinary albumin to creatinine ratio and serum creatinine concentration at baseline were 173.3 (47.2) mg/g creatinine and 0.78 (0.19) mg/dl. Sixty-eight per cent of the patients had hypertension at baseline. Mean (SD) systolic and diastolic blood pressures at baseline were 137.1 (14.6) and 77.5 (10.3) mmHg. The INNOVATION study will determine whether telmisartan, an angiotensin II receptor blocker, provides clinical benefits in hypertensive or normotensive patients with diabetes mellitus and diabetic nephropathy.
Collapse
Affiliation(s)
- H Makino
- Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Abstract
After several years of treatment for type 2 diabetes mellitus, a 69-year-old Japanese man developed an acute painful neuropathy, characterized by bilateral causalgia and dysaesthesia in his cheeks and around his eyes, typically 30 min to 3h after meals. As his glycaemic control deteriorated, his haemoglobin (Hb) A1c level gradually increased from 7-8% to 10.3% and his symptoms became more severe. The pain radiated out along the distribution of the ophthalmic and maxillary divisions of the trigeminal nerve. The patient was treated with insulin therapy and his HbA1c level decreased from 10.3% to 6.8% within 7 months. Five months after initiating insulin therapy, his symptoms showed a dramatic improvement. This was a very unusual case of bilateral acute painful neuropathy that involved the ophthalmic and maxillary divisions of the trigeminal nerve, and in which aggravation of the symptoms clearly related to poor glycaemic control.
Collapse
Affiliation(s)
- S Takayama
- Diabetes Centre, Tokyo Women's Medical University School of Medicine, Tokyo, Japan.
| | | | | | | |
Collapse
|
35
|
Yamashita M, Takahashi R, Kokubo M, Takayama K, Tanabe H, Sueoka M, Ishii M, Okuuchi N, Iwamoto Y, Tachibana H. SU-F-T-268: A Feasibility Study of Independent Dose Verification for Vero4DRT. Med Phys 2016. [DOI: 10.1118/1.4956408] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
36
|
Ogawa T, Uota M, Ikebe K, Notomi Y, Iwamoto Y, Shirobayashi I, Kibi M, Masayasu S, Sasaki S, Maeda Y. Taste detection ability of elderly nursing home residents. J Oral Rehabil 2016; 43:505-10. [DOI: 10.1111/joor.12394] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/13/2016] [Indexed: 11/30/2022]
Affiliation(s)
- T. Ogawa
- Department of Prosthodontics; Gerodontology and Oral Rehabilitation; Osaka University Graduate School of Dentistry; Osaka Japan
| | - M. Uota
- Department of Prosthodontics; Gerodontology and Oral Rehabilitation; Osaka University Graduate School of Dentistry; Osaka Japan
| | - K. Ikebe
- Department of Prosthodontics; Gerodontology and Oral Rehabilitation; Osaka University Graduate School of Dentistry; Osaka Japan
| | - Y. Notomi
- Shitennoji-Yawaragien Welfare Facility for the Disabled; Tondabayashi Osaka Japan
| | - Y. Iwamoto
- Slowlife Yao Long-term Care Health Facility; Yao Osaka Japan
| | - I. Shirobayashi
- Clover-no-Oka Long-term Care Health Facility; Kawachinagano Osaka Japan
| | - M. Kibi
- Department of Prosthodontics; Gerodontology and Oral Rehabilitation; Osaka University Graduate School of Dentistry; Osaka Japan
| | - S. Masayasu
- Ikurien-Naka Special Elderly Nursing Home; Sugaya Naka Ibaragi Japan
| | - S. Sasaki
- Department of Social and Preventive Epidemiology; School of Public Health; The University of Tokyo; Bunkyo Tokyo Japan
| | - Y. Maeda
- Department of Prosthodontics; Gerodontology and Oral Rehabilitation; Osaka University Graduate School of Dentistry; Osaka Japan
| |
Collapse
|
37
|
Kubota K, Kobayakaya K, Okada S, Shiba K, Iwamoto Y. Hyperglycemia During Acute Spinal Cord Injury Is a Detrimental Factor That Impairs Functional Improvement in Acute C3-C4 Cervical Cord Injury Patients Without Any Bony Damages. Intensive Care Med Exp 2015. [PMCID: PMC4797914 DOI: 10.1186/2197-425x-3-s1-a33] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
38
|
Kuwashima U, Okazaki K, Tashiro Y, Mizu-Uchi H, Hamai S, Okamoto S, Murakami K, Iwamoto Y. Correction of coronal alignment correlates with reconstruction of joint height in unicompartmental knee arthroplasty. Bone Joint Res 2015. [PMID: 26261235 PMCID: PMC4672364 DOI: 10.1302/2046-3758.47.2000416] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
OBJECTIVES Because there have been no standard methods to determine pre-operatively the thickness of resection of the proximal tibia in unicompartmental knee arthroplasty (UKA), information about the relationship between the change of limb alignment and the joint line elevation would be useful for pre-operative planning. The purpose of this study was to clarify the correlation between the change of limb alignment and the change of joint line height at the medial compartment after UKA. METHODS A consecutive series of 42 medial UKAs was reviewed retrospectively. These patients were assessed radiographically both pre- and post-operatively with standing anteroposterior radiographs. The thickness of bone resection at the proximal tibia and the distal femur was measured radiographically. The relationship between the change of femorotibial angle (δFTA) and the change of joint line height, was analysed. RESULTS The mean pre- and post-operative FTA was 180.5° (172.2° to 184.8°) and 175.0° (168.5° to 178.9°), respectively. The mean δFTA was 5.5° (2.3° to 10.1°). The joint line elevation of the tibia (JLET) was 4.4 mm (2.1 to 7.8). The δFTA was correlated with the JLET (correlation coefficient 0.494, p = 0.0009). CONCLUSIONS This study indicated that there is a significant correlation between the change of limb alignment and joint line elevation. This observation suggests that it is possible to know the requirement of elevation of the joint line to obtain the desired correction of limb alignment, and to predict the requirement of bone resection of the proximal tibia pre-operatively. Cite this article: Bone Joint Res 2015;4:128-133.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - Y. Iwamoto
- Kyushu University, 3-1-1
Maidashi, Higashi-ku, Fukuoka, 812-0054 Japan
| |
Collapse
|
39
|
Kuwashima U, Okazaki K, Tashiro Y, Mizu-Uchi H, Hamai S, Okamoto S, Murakami K, Iwamoto Y. Correction of coronal alignment correlates with reconstruction of joint height in unicompartmental knee arthroplasty. Bone Joint Res 2015; 4:128-33. [DOI: 10.1302/2046-3758.48.2000416] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
Objectives Because there have been no standard methods to determine pre-operatively the thickness of resection of the proximal tibia in unicompartmental knee arthroplasty (UKA), information about the relationship between the change of limb alignment and the joint line elevation would be useful for pre-operative planning. The purpose of this study was to clarify the correlation between the change of limb alignment and the change of joint line height at the medial compartment after UKA. Methods A consecutive series of 42 medial UKAs was reviewed retrospectively. These patients were assessed radiographically both pre- and post-operatively with standing anteroposterior radiographs. The thickness of bone resection at the proximal tibia and the distal femur was measured radiographically. The relationship between the change of femorotibial angle (δFTA) and the change of joint line height, was analysed. Results The mean pre- and post-operative FTA was 180.5° (172.2° to 184.8°) and 175.0° (168.5° to 178.9°), respectively. The mean δFTA was 5.5° (2.3° to 10.1°). The joint line elevation of the tibia (JLET) was 4.4 mm (2.1 to 7.8). The δFTA was correlated with the JLET (correlation coefficient 0.494, p = 0.0009). Conclusions This study indicated that there is a significant correlation between the change of limb alignment and joint line elevation. This observation suggests that it is possible to know the requirement of elevation of the joint line to obtain the desired correction of limb alignment, and to predict the requirement of bone resection of the proximal tibia pre-operatively. Cite this article: Bone Joint Res 2015;4:128–133
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - Y. Iwamoto
- Kyushu University, 3-1-1
Maidashi, Higashi-ku, Fukuoka, 812-0054 Japan
| |
Collapse
|
40
|
Osonoi T, Onishi Y, Nishida T, Hyllested-Winge J, Iwamoto Y. Insulin degludec versus insulin glargine, both once daily as add-on to existing orally administered antidiabetic drugs in insulin-naive Japanese patients with uncontrolled type 2 diabetes: subgroup analysis of a pan-Asian, treat-to-target phase 3 trial. Diabetol Int 2015; 7:141-147. [PMID: 30603257 DOI: 10.1007/s13340-015-0221-3] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/02/2015] [Accepted: 06/26/2015] [Indexed: 11/24/2022]
Abstract
Insulin degludec (IDeg) is a novel basal insulin analogue with an ultralong duration of action that provides flat and stable reductions in blood glucose. The BEGIN ONCE ASIA trial was a phase 3 pan-Asian study examining the efficacy and safety of IDeg once daily (OD) versus insulin glargine (IGlar) OD in insulin-naive patients with type 2 diabetes (T2D). In this multinational, 26-week, open-label, treat-to-target trial, participants were randomised (2:1) to IDeg OD or IGlar OD, administered with one or more antidiabetic drugs (OAD) per os. Here we report the results from a post hoc analysis of Japanese patients enrolled in the trial [n = 133; 63.2 % male; mean age 61.0 years; mean body mass index 24.1 kg/m2; mean glycosylated haemoglobin (HbA1c) 8.5 %]. After 26 weeks, mean HbA1c levels were similar between the two groups [estimated mean treatment difference 0.11 %; 95 % confidence interval (CI) -0.09, 0.31]. Confirmed hypoglycaemia was reported in 53.4 and 61.4 % of patients in the IDeg OD and IGlar OD groups [rate ratio (IDeg/IGlar) 0.87; 95 % CI 0.51, 1.48]. Confirmed nocturnal hypoglycaemia was reported in 17.0 and 22.7 % of patients in the IDeg OD and IGlar OD groups, respectively [rate ratio (IDeg/IGlar) 0.50; 95 % CI 0.19, 1.32]. Adverse event rates were similar between treatment groups. Initiating insulin treatment with IDeg OD in Japanese patients with T2D, inadequately maintained on OADs and requiring treatment intensification, provided effective glycaemic control with low rates of confirmed and nocturnal confirmed hypoglycaemia.
Collapse
Affiliation(s)
- T Osonoi
- Internal Medicine, Naka Memorial Clinic, 745-5 Nakadai, Naka-shi, Ibaraki 311-0113 Japan
| | - Y Onishi
- 2The Institute for Adult Diabetes, Asahi Life Foundation, 2-2-6, Nihonbashi, Bakurocho, Chuo-ku, Tokyo, 103-0002 Japan
| | - T Nishida
- Novo Nordisk Pharma Ltd, Meiji Yasuda Seimei Building, 2-1-1 Marunouchi, Chiyoda-Ku, Tokyo, 100-0005 Japan
| | - J Hyllested-Winge
- Novo Nordisk Pharma Ltd, Meiji Yasuda Seimei Building, 2-1-1 Marunouchi, Chiyoda-Ku, Tokyo, 100-0005 Japan
| | - Y Iwamoto
- 2The Institute for Adult Diabetes, Asahi Life Foundation, 2-2-6, Nihonbashi, Bakurocho, Chuo-ku, Tokyo, 103-0002 Japan
| |
Collapse
|
41
|
Okada T, Ikezoe R, Ichimura M, Hirata M, Yokoyama T, Iwamoto Y, Sumida S, Takeyama K, Jang S, Yoshikawa M, Kohagura J, Shima Y. Internal Measurement of Propagation of ICRF Waves by Using Reflectometers on GAMMA 10. Fusion Science and Technology 2015. [DOI: 10.13182/fst14-898] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- T. Okada
- University of Tsukuba, Plasma Research Center, Tsukuba, Japan
| | - R. Ikezoe
- University of Tsukuba, Plasma Research Center, Tsukuba, Japan
| | - M. Ichimura
- University of Tsukuba, Plasma Research Center, Tsukuba, Japan
| | - M. Hirata
- University of Tsukuba, Plasma Research Center, Tsukuba, Japan
| | - T. Yokoyama
- University of Tsukuba, Plasma Research Center, Tsukuba, Japan
| | - Y. Iwamoto
- University of Tsukuba, Plasma Research Center, Tsukuba, Japan
| | - S. Sumida
- University of Tsukuba, Plasma Research Center, Tsukuba, Japan
| | - K. Takeyama
- University of Tsukuba, Plasma Research Center, Tsukuba, Japan
| | - S. Jang
- University of Tsukuba, Plasma Research Center, Tsukuba, Japan
| | - M. Yoshikawa
- University of Tsukuba, Plasma Research Center, Tsukuba, Japan
| | - J. Kohagura
- University of Tsukuba, Plasma Research Center, Tsukuba, Japan
| | - Y. Shima
- University of Tsukuba, Plasma Research Center, Tsukuba, Japan
| |
Collapse
|
42
|
Osaki K, Okazaki K, Takayama Y, Mzu-uchi H, Hamai S, Kuwashima U, Murakami K, Kawanami S, Honda H, Iwamoto Y. FRI0045 Evaluation of Articular Cartilage Change of Knee Joint in Rheumatoid Arthritis Using T1ρ Mapping Magnetic Resonance Imaging. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.4283] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
43
|
Hirai F, Yamanaka T, Taguchi K, Daga H, Ono A, Tanaka K, Kogure Y, Shimizu J, Kimura T, Fukuoka J, Iwamoto Y, Sasaki H, Takeda K, Seto T, Ichinose Y, Nakagawa K, Nakanishi Y. A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L. Ann Oncol 2014; 26:363-8. [PMID: 25403584 DOI: 10.1093/annonc/mdu541] [Citation(s) in RCA: 70] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
BACKGROUND Thymic carcinoma (TC) is an exceptionally rare tumor, which has a very poor prognosis differing from thymoma. Till date, there has been no report of any results of clinical trials focusing on TC. The role of non-anthracycline-based chemotherapy has not been elucidated since the previous studies included a relatively small number of TC patients. This single-arm study evaluated carboplatin and paclitaxel (CbP) in chemotherapy-naive patients with advanced TC. PATIENTS AND METHODS The study treatment consisted of carboplatin (area under the curve 6) and paclitaxel (200 mg/m(2)) every 3 weeks for a maximum of six cycles. The primary end point was objective response rate (ORR) by independent review. The secondary end points included overall survival (OS), progression-free survival (PFS), and safety. Based on the SWOG 2-stage design, the planned sample size of 40 patients was determined to reject the ORR of 20% under the expectation of 40% with a power of 0.85 and a type I error of 0.05. RESULTS Forty patients from 21 centers were enrolled for this study from May 2008 to November 2010. Of the 39 patients evaluable for analysis, 36 were pathologically diagnosed by independent review, and 97% patients were eventually TC. There was 1/13 complete/partial responses with an ORR of 36% (95% confidence interval 21%-53%; P = 0.031). The median PFS was 7.5 (6.2-12.3) months, while OS did not reach the median value. Major adverse event was grade 3-4 neutropenia in 34 patients (87%). There was no treatment-related death. CONCLUSIONS In this largest trial with TC, CbP showed promising efficacy in advanced TC when compared with anthracycline-based chemotherapy, which is the current standard treatment of thymic neoplasm. Our results established that CbP, one of the standard treatments for non-small-cell lung cancer, might be an option as a chemotherapy regimen for TC.
Collapse
Affiliation(s)
- F Hirai
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka
| | - T Yamanaka
- Department of Biostatistics, Yokohama City University, Yokohama
| | - K Taguchi
- Department of Pathology, National Kyushu Cancer Center, Fukuoka
| | - H Daga
- Department of Clinical Oncology, Osaka City General Hospital, Osaka
| | - A Ono
- Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka
| | - K Tanaka
- Department of Medical Oncology, Kinki University Faculty of Medicine, Osaka
| | - Y Kogure
- Department of Respiratory Medicine, National Hospital Organization, Nagoya Medical Center, Nagoya
| | - J Shimizu
- Department of Thoracic Oncology, Aichi Cancer Center Hospital, Nagoya
| | - T Kimura
- Department of Respiratory Medicine, Graduate School of Medicine, Osaka City University, Osaka
| | - J Fukuoka
- Department of Pathology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki
| | - Y Iwamoto
- Department of Medical Oncology, Hiroshima City Hospital, Hiroshima
| | - H Sasaki
- Department of Oncology, Immunology and Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi
| | - K Takeda
- Department of Clinical Oncology, Osaka City General Hospital, Osaka
| | - T Seto
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka
| | - Y Ichinose
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka
| | - K Nakagawa
- Department of Medical Oncology, Kinki University Faculty of Medicine, Osaka
| | - Y Nakanishi
- Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | | |
Collapse
|
44
|
Kobayakawa K, Kumamaru H, Saiwai H, Kubota K, Ohkawa Y, Kishimoto J, Yokota K, Ideta R, Shiba K, Tozaki-Saitoh H, Inoue K, Iwamoto Y, Okada S. Acute hyperglycemia impairs functional improvement after spinal cord injury in mice and humans. Sci Transl Med 2014; 6:256ra137. [DOI: 10.1126/scitranslmed.3009430] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
|
45
|
Yashima H, Sekimoto S, Ninomiya K, Kasamatsu Y, Shima T, Takahashi N, Shinohara A, Matsumura H, Satoh D, Iwamoto Y, Hagiwara M, Nishiizumi K, Caffee MW, Shibata S. Measurements of the neutron activation cross sections for Bi and Co at 386 MeV. Radiat Prot Dosimetry 2014; 161:139-143. [PMID: 24368868 DOI: 10.1093/rpd/nct334] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
Neutron activation cross sections for Bi and Co at 386 MeV were measured by activation method. A quasi-monoenergetic neutron beam was produced using the (7)Li(p,n) reaction. The energy spectrum of these neutrons has a high-energy peak (386 MeV) and a low-energy tail. Two neutron beams, 0° and 25° from the proton beam axis, were used for sample irradiation, enabling a correction for the contribution of the low-energy neutrons. The neutron-induced activation cross sections were estimated by subtracting the reaction rates of irradiated samples for 25° irradiation from those of 0° irradiation. The measured cross sections were compared with the findings of other studies, evaluated in relation to nuclear data files and the calculated data by Particle and Heavy Ion Transport code System code.
Collapse
Affiliation(s)
- H Yashima
- Research Reactor Institute, Kyoto University, Kumatori, Osaka 590-0494, Japan
| | - S Sekimoto
- Research Reactor Institute, Kyoto University, Kumatori, Osaka 590-0494, Japan
| | - K Ninomiya
- Graduate School of Science, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - Y Kasamatsu
- Graduate School of Science, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - T Shima
- Research Center for Nuclear Physics, Osaka University, Suita, Osaka 567-0047, Japan
| | - N Takahashi
- Graduate School of Science, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - A Shinohara
- Graduate School of Science, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - H Matsumura
- High Energy Accelerator Research Organization, Tsukuba, Ibaraki 305-0801, Japan
| | - D Satoh
- Japan Atomic Energy Agency, Tokai-mura, Naka-gun, Ibaraki 319-1195, Japan
| | - Y Iwamoto
- Japan Atomic Energy Agency, Tokai-mura, Naka-gun, Ibaraki 319-1195, Japan
| | - M Hagiwara
- High Energy Accelerator Research Organization, Tsukuba, Ibaraki 305-0801, Japan
| | - K Nishiizumi
- Space Sciences Laboratory, University of California, Berkeley, CA 94720-7450, USA
| | - M W Caffee
- Department of Physics, Purdue University, West Lafayette, IN 47907, USA
| | - S Shibata
- Research Reactor Institute, Kyoto University, Kumatori, Osaka 590-0494, Japan
| |
Collapse
|
46
|
Yamada S, Uchida K, Iwamoto Y, Sugino N, Yoshinari N, Kagami H, Taguchi A. Panoramic radiography measurements, osteoporosis diagnoses and fractures in Japanese men and women. Oral Dis 2014; 21:335-41. [PMID: 25135460 DOI: 10.1111/odi.12282] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2014] [Accepted: 08/05/2014] [Indexed: 11/30/2022]
Abstract
OBJECTIVES The purpose of this study was to investigate the association of the shape of the mandibular cortex on panoramic radiographs with the risk of an osteoporosis diagnosis without prevalent fractures and with the risk of osteoporotic fractures in Japanese men and women. SUBJECTS AND METHODS One thousand and twenty-one subjects aged 40-89 years, who visited our university hospital and underwent panoramic radiography between 2007 and 2013, participated in this study. Eighty-eight patients received a diagnosis of osteoporosis without prevalent fractures, and 55 were diagnosed with osteoporotic fractures. Blinded to the groupings, we classified the shape of the mandibular cortex on panoramic radiographs as normal, moderately eroded or severely eroded. RESULTS After adjustment for confounding factors, the odds ratios for an osteoporosis diagnosis associated with moderately eroded and severely eroded mandibular cortices were 1.4 (95% CI, 0.8-2.6) and 2.6 (95% CI, 1.4-5.0), respectively. The odds ratios for an osteoporotic fracture associated with moderately eroded and severely eroded cortices were 0.8 (95% CI, 0.4-1.7) and 1.1 (95% CI, 0.5-2.5), respectively. CONCLUSIONS Subjects in Japan with eroded mandibular cortices tended to be at increased risk of osteoporosis diagnoses but not of fractures.
Collapse
Affiliation(s)
- S Yamada
- Department of Hard Tissue Research, Graduate School of Oral Medicine, Matsumoto Dental University, Shiojiri, Japan
| | | | | | | | | | | | | |
Collapse
|
47
|
Nishiyama A, Katakami N, Morita S, Seto T, Iwamoto Y, Hirashima T, Kaneda H, Kawaguchi T, Matsuoka H, Yokota S, Nishimura T, Okada M, Fujita M, Shibata K, Urata Y, Yamamoto N, Nakagawa K, Nakanishi Y. Randomized Phase III Study Comparing Gefitinib (G) with Erlotinib (E) in Patients (Pts) with Previously Treated Advanced Lung Adenocarcinoma (La): Wjog 5108L. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu349.50] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
48
|
Katakami N, Yoshioka H, Okamoto H, Iwamoto Y, Seto T, Takahashi T, Sunaga N, Kudoh S, Chikamori K, Harada M, Tanaka H, Saka H, Takeda K, Nogami N, Masuda N, Harada T, Yamamoto N, Nakagawa K. Amrubicin (Amr) Versus Docetaxel (Dtx) As Second- or Third-Line Treatment for Non-Small Cell Lung Cancer (Nsclc): a Randomized Phase III Trial. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu349.15] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
49
|
Kataoka K, Tanaka K, Mizusawa J, Kimura A, Hiraga H, Kawai A, Matsunobu T, Matsumine A, Araki N, Oda Y, Fukuda H, Iwamoto Y. A Randomized Phase II/III Trial of Perioperative Chemotherapy with Adriamycin Plus Ifosfamide Versus Gemcitabine Plus Docetaxel for High-grade Soft Tissue Sarcoma: Japan Clinical Oncology Group Study JCOG1306. Jpn J Clin Oncol 2014; 44:765-9. [DOI: 10.1093/jjco/hyu080] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
50
|
Wheeler DC, Abdalla S, Chertow G, Parfrey P, Herzog C, Mikolasevic I, Racki S, Lukenda V, Milic S, Devcic B, Orlic L, Suttorp MM, Hoekstra T, Ocak G, Van Diepen ATN, Ott I, Mittelman M, Rabelink TJ, Krediet RT, Dekker FW, Simone S, Dell'Oglio MPS, Ciccone M, Corciulo R, Castellano G, Balestra C, Grandaliano G, Gesualdo L, Pertosa G, Nishida M, Ando M, Karasawa K, Iwamoto Y, Tsuchiya K, Nitta K, Krzanowski M, Janda K, Gajda M, Dumnicka P, Fedak D, Lis G, Ja kowski P, Litwin JA, Su owicz W, Freitas GR, Silva VB, Abensur H, Luders C, Pereira BJ, Castro MC, Oliverira RB, Moyses RM, Elias RM, Silva BC, Tekce H, Ozturk S, Aktas G, Kin Tekce B, Erdem A, Ozyasar M, Taslamacioglu Duman T, Yazici M, Kirkpantur A, Balci MM, Turkvatan A, Afsar B, Alkis M, Mandiroglu F, Voroneanu L, Siriopol D, Nistor I, Apetrii M, Hogas S, Onofriescu M, Covic A, An WS, Kim SE, Son YK, Oh YJ, Gelev S, Toshev S, Trajceska L, Selim G, Dzekova P, Shikole A, Park J, Lee JS, Shin ES, Ann SH, Kim SJ, Chung HC, Janda K, Krzanowski M, Gajda M, Dumnicka P, Fedak D, Lis G, Litwin JA, Sulowicz W, Elewa U, Bichari W, Abo-Seif K, Seferi S, Rroji M, Likaj E, Spahia N, Barbullushi M, Thereska N, Kopecky CM, Genser B, Maerz W, Wanner C, Saemann MD, Weichhart T, Sezer S, Gurlek Demirci B, Tutal E, Bal Z, Erkmen Uyar M, Ozdemir Acar FN, Macunluoglu B, Atakan A, Ari Bakir E, Georgianos P, Sarafidis PA, Stamatiadis DN, Liakopoulos V, Zebekakis PE, Papagianni A, Lasaridis AN, Eftimovska - Otovic N, Babalj-Banskolieva E, Kostadinska-Bogdanoska S, Grozdanovski R, Aono M, Sato Y, El Amrani M, Asserraji M, Benyahia M, Lee YK, Choi SR, Cho A, Kim JK, Choi MJ, Kim SJ, Yoon JW, Koo JR, Kim HJ, Noh JW, Inagaki H, Yokota N, Sato Y, Chiyotanda S, Fukami K, Fujimoto S, Kendi Celebi Z, Kutlay S, Sengul S, Nergizoglu G, Erturk S, Ates K, Vishnevskii KA, Rumyantsev AS, Zemchenkov AY, Smirnov AV, Reinhardt B, Knaup R, Esteve Simo V, Carneiro Oliveira J, Moreno Guzman F, Fulquet Nicolas M, Pou Potau M, Saurina Sole A, Duarte Gallego V, Ramirez De Arellano Serna M, Turkmen K, Demirtas L, Akbas EM, Bakirci EM, Buyuklu M, Timuroglu A, Georgianos PI, Sarafidis PA, Karpetas A, Liakopoulos V, Stamatiadis DN, Papagianni A, Lasaridis AN, Taira T, Nohtomi K, Takemura T, Chiba T, Hirano T, Chang CT, Huang CC, Chen CJ, El Amrani M, Mohamed A, Benyahia M, Kanai H, Tamura Y, Kaizu Y, Kali A, Yayar O, Erdogan B, Eser B, Ercan Z, Buyukbakkal M, Merhametsiz O, Haspulat A, Yildirim T, Bozkurt B, Ayli MD, Bal Z, Erkmen Uyar M, Gokustun D, Gurlek Demirci B, Tutal E, Sezer S, Markaki A, Grammatikopoulou M, Fragkiadakis G, Stylianou K, Venyhaki M, Chatzi V, Selim G, Stojceva-Taneva O, Tozija L, Dzekova-Vidimliski P, Trajceska L, Gelev S, Petronievic Z, Sikole A, Moyseyenko V, Nykula T, Fernandes RT, Barreto DV, Rodrigues GGC, Misael A, Branco-Martins CT, Barreto FC, Yayar O, Ercan Z, Eser B, Merhametsiz O, Haspulat A, Buyukbakkal M, Erdogan B, Yildirim T, Bozkurt B, Ayli MD. DIALYSIS CARDIOVASCULAR COMPLICATIONS 1. Nephrol Dial Transplant 2014. [DOI: 10.1093/ndt/gfu155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|